Nusinersen · Spinraza

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Spinal Muscular Atrophy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of infantile spinal muscular atrophy
Product first approved 2017PMDA
EU
  • Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Spinal Muscular Atrophy
NCT07846696 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2026-09-17 – 2028-12-31 · SMA - Spinal Muscular Atrophy
What this study did
NCT04089566 · Biogen
2020-03-26 – 2024-05-30 · Muscular Atrophy, Spinal
What this study did
NCT02594124 · Biogen
2015-11-04 – 2023-08-21 · Spinal Muscular Atrophy
What this study did
Phase 2 (4)
Spinal Muscular Atrophy
NCT07047144 · Scholar Rock, Inc.
2025-09-15 – 2029-03 · Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
What this study did
NCT02462759 · Biogen
2015-08-19 – 2018-09-24 · Spinal Muscular Atrophy
What this study did
Phase 1/2 (1)
Spinal Muscular Atrophy
Phase 1 (5)
Phase 4 (1)
Early phase / not applicable (4)
Spinal Muscular Atrophy
NCT07838779 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2026-09-17 – 2028-12-31 · SMA - Spinal Muscular Atrophy
What this study did
NCT04159987 · Centre Hospitalier Universitaire de Nice
2020-02-25 – 2025-12-31 · Spinal Muscular Atrophy
What this study did
NCT04576494 · CHU de Reims
2022-01-24 – 2023-09-08 · Spinal Muscular Atrophy
What this study did
Other / comorbidity
NCT04674618 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-12-14 – 2023-12-21 · Muscular Atrophy, Spinal, Ultrasound
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Spinal Muscular Atrophy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nusinersen (Spinraza): this drugApprovedRNA / oligonucleotideSMN2 pre-mRNAWeak signal
NCT02292537: Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9)
NCT01839656: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants
Apitegromab (Isembyld)ApprovedMonoclonal antibodyMyostatin (pro/latent form)not yet gradedNo reviewed efficacy summary in this indication
Risdiplam (Evrysdi)ApprovedSmall moleculeSMN2 pre-mRNAnot yet gradedNo reviewed efficacy summary in this indication
Taldefgrobep AlfaPhase 3Antibody-derived scaffoldActivin/myostatin type II receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Spinraza (Nusinersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (2)
Phase 3Spinal Muscular AtrophyActive not recruiting
Est. primary completion 2027-09-24 · NCT05067790 · CT.gov ↗
What to watch
Phase 1Spinal Muscular AtrophyRecruiting
Est. primary completion 2027-09-30 · NCT06555419 · CT.gov ↗
What to watch
2028 (3)
November 2028 (1)
Phase 2Spinal Muscular AtrophyRecruiting
Est. primary completion 2028-11 · NCT07047144 · CT.gov ↗
What to watch
December 2028 (2)
Phase 3Spinal Muscular AtrophyNot yet recruiting
Est. primary completion 2028-12-31 · NCT07846696 · CT.gov ↗
What to watch
Early phase / not applicableSpinal Muscular AtrophyNot yet recruiting
Est. primary completion 2028-12-31 · NCT07838779 · CT.gov ↗
What to watch

See the full readout calendar ↗